NTx Bio Platform Supports Personalized mRNA Vaccine Manufacturing for Phase 1 Melanoma Trial
NTx Bio, a company developing next-generation biomanufacturing technologies, announced that its NTxscribe® CORE platform is being used by researchers at Baylor College of Medicine to manufacture messenger RNA (mRNA) for a personalized dendritic cell vaccine currently being evaluated in an industry-sponsored Phase 1 clinical trial for patients with refractory melanoma.
The application represents one of the first publicly disclosed examples of NTx Bio’s continuous-flow manufacturing technology being translated into a clinical development program. The technology is being incorporated into the manufacturing workflow for Diakonos Oncology’s DOC1021, also known as dubodencel, a personalized dendritic cell vaccine platform designed to stimulate a patient’s immune system to recognize and attack tumor cells.
The collaboration highlights the growing importance of scalable and reproducible manufacturing technologies in personalized cancer therapies. Unlike conventional medicines that can be produced in large, standardized batches, personalized cell and gene therapies often begin with biological material collected from an individual patient. This creates significant manufacturing challenges because every patient can present a different starting material, requiring processes that are flexible, reliable, and capable of producing consistent therapeutic components.
At Baylor College of Medicine, researchers are using the NTxscribe CORE platform to amplify tumor-derived mRNA obtained from very small surgical biopsy samples. This step is critical to the production of the personalized vaccine because the amplified mRNA provides information about the patient’s tumor and helps preserve a broad representation of the tumor’s antigenic profile.
Supporting Personalized Cancer Vaccine Manufacturing
DOC1021 is being developed as a personalized immunotherapy intended to harness the patient’s own immune system against cancer.
The approach begins with tumor material collected from the patient. Because the genetic and molecular characteristics of tumors vary from person to person, the resulting vaccine is designed around each patient’s individual tumor profile.
One of the central challenges in this process is obtaining enough high-quality tumor-derived RNA from small biopsy samples for downstream manufacturing. Traditional amplification approaches can involve multiple manual steps, specialized equipment, and highly trained personnel.
NTx Bio’s technology is being used to address this part of the workflow.
The NTxscribe platform amplifies mRNA while maintaining the full-length range of the patient’s tumor transcriptome. Preserving longer RNA sequences is important because it helps maintain a more complete representation of the tumor’s molecular information.
By producing amplified mRNA that retains the characteristics of the original tumor transcriptome, the process is intended to provide vaccine developers with a more comprehensive source of tumor-associated antigens.
This capability is particularly relevant for personalized cancer vaccines, where the objective is to generate an immune response against multiple characteristics of an individual patient’s tumor rather than relying on a single predefined target.
Refractory Melanoma Represents a Significant Unmet Need
The manufacturing technology is currently supporting a Phase 1 clinical trial evaluating DOC1021 in patients with refractory melanoma.
These patients represent a particularly challenging population because their disease has stopped responding adequately to standard treatment approaches, including immune checkpoint inhibitors. Once melanoma becomes resistant to available therapies, treatment options can become limited, creating a significant need for innovative therapeutic strategies.
DOC1021 is designed to use the patient’s own immune cells as part of a personalized approach to cancer treatment.
The dendritic cell vaccine platform aims to expose and activate immune cells using tumor-derived information, with the goal of generating a targeted immune response against malignant cells.
The personalized nature of the treatment makes manufacturing a critical component of the overall therapeutic strategy. Each patient’s biological starting material can differ substantially, meaning that manufacturing processes must accommodate individual variability without compromising consistency or quality.
NTx Bio believes that its automated mRNA amplification technology could help address some of these challenges.
Addressing Manufacturing Variability
Joan Haab, Ph.D., chief executive officer of NTx Bio, said manufacturing consistency is one of the less visible but important challenges associated with personalized cell and gene therapies.
Many personalized therapies rely heavily on manual manufacturing procedures. Although these processes can be effective, manual operations can introduce variability from operator to operator and from batch to batch.
For therapies manufactured individually for patients, even relatively small variations in processing can create challenges for quality control, reproducibility, and production timelines.
The use of NTxscribe in the Baylor and Diakonos workflow provides an example of how automation can potentially address these issues.
According to NTx Bio, the platform can help transform the mRNA production step from a labor-intensive procedure into a more standardized and controlled process.
Haab noted that seeing the NTxscribe platform support the DOC1021 program through the journey from patient-derived tumor material to a clinical dose represents an important validation of the company’s technology.
Baylor Researchers Highlight Reproducibility
The technology has also received positive feedback from researchers involved in developing the DOC1021 platform.
William Decker, Ph.D., professor of Pathology & Immunology at Baylor College of Medicine and inventor of the DOC1021 technology, emphasized that patient-derived material does not provide researchers with a standardized starting point.
Tumor samples can vary in size, composition, and molecular characteristics. These differences can make manual processing particularly time-consuming and difficult to standardize.
According to Decker, automating the mRNA generation stage with NTxscribe addresses one of the most challenging and variable components of the manufacturing process.
By reducing the amount of manual intervention required, researchers can devote more attention to other aspects of producing and delivering the personalized therapeutic product.
Vanaja Konduri, Ph.D., assistant professor of Immunology and an inventor of the mRNA amplification procedure, similarly highlighted improvements in reproducibility.
Konduri reported that the NTxscribe platform has significantly improved process consistency while virtually eliminating batch-to-batch variability in the relevant workflow.
Such reproducibility could become increasingly important as personalized therapies move from early research toward larger clinical development programs.
Continuous-Flow Technology
NTxscribe CORE uses a continuous-flow manufacturing architecture based on a hollow fiber bioreactor, or HFBR.
The same underlying technology is also incorporated into NTx Bio’s recently launched NTxscribe FLEX system.
Continuous-flow processing is intended to provide a more controlled manufacturing environment while reducing the number of individual manual operations involved in producing purified mRNA.
This approach can be particularly useful for translational and clinical programs where researchers need to produce consistent material repeatedly while working with limited patient-derived starting material.
NTx Bio is positioning the technology as a platform that can support applications ranging from early research through clinical manufacturing.
Automation Reduces Manual Work
One of the primary benefits of the NTxscribe platform is its ability to automate mRNA generation.
Traditional processes can require multiple pieces of equipment and numerous hands-on operations. Such workflows may require skilled personnel to perform individual steps and monitor the process throughout production.
Automation can reduce these requirements by integrating more of the manufacturing process into a single system.
For personalized therapies, this could be particularly valuable because manufacturing teams may need to process material from multiple patients using individualized workflows.
Reducing manual intervention may also help laboratories establish more consistent procedures and decrease the potential for operator-dependent variation.
Reproducible Production and Quality
Consistency is another major consideration for clinical manufacturing.
NTx Bio says its automated approach is designed to provide reproducible output by reducing manual steps and eliminating certain individual unit operations.
For a personalized therapeutic program, reproducibility does not necessarily mean that every patient’s final product is identical. Rather, it means that the manufacturing process can operate consistently within defined quality parameters despite differences in patient starting material.
Maintaining that level of process control may be important as personalized vaccines progress through clinical development.
Demonstrating a reliable manufacturing process can also help support regulatory requirements and facilitate the transition from early-stage clinical testing to larger studies.
Flexible Manufacturing and Scalability
The NTxscribe platform is also designed to simplify changeover between patient samples.
Its single-use, fully closed cassettes can allow laboratories to transition between samples without extensive equipment cleaning or reconfiguration.
This feature could be especially relevant to personalized medicine programs, in which each patient may require an individualized manufacturing workflow.
The platform also offers a potential pathway toward increased production capacity.
While early-stage clinical programs may require relatively modest production volumes, successful therapies could eventually need to support significantly larger numbers of patients.
A manufacturing technology capable of scaling alongside clinical development could therefore provide an advantage as programs advance.
Supporting Clinical Translation
Another potential benefit of NTxscribe is its suitability for translational and early clinical programs.
The benchtop format allows researchers to use the technology in relatively compact laboratory environments, while the underlying manufacturing approach is designed to support higher production volumes as requirements increase.
This combination could help shorten the transition from laboratory research to clinical development.
For personalized cell and gene therapies, manufacturing can often become a bottleneck between scientific discovery and patient treatment. Even when a therapeutic concept demonstrates strong biological potential, complicated production requirements can delay clinical development.
By automating a key step in the manufacturing process, NTx Bio aims to help developers move personalized therapies forward more efficiently.
Broader Implications for Personalized Medicine
The use of NTxscribe in the DOC1021 program reflects a broader trend toward integrating advanced manufacturing technologies into personalized medicine.
Cancer therapies are increasingly being designed around the unique molecular characteristics of individual tumors. Personalized vaccines, cell therapies, and other individualized treatments may offer opportunities to target cancer in ways that conventional therapies cannot.
However, personalization also creates manufacturing complexity.
Every patient may require a separate production process, and developers must maintain strict standards for quality, identity, purity, and consistency.
Technologies capable of automating and standardizing critical manufacturing steps could therefore play an increasingly important role in the development of these therapies.
The experience at Baylor College of Medicine provides an early clinical example of how continuous-flow mRNA manufacturing could be incorporated into such a personalized therapeutic workflow.
NTx Bio’s involvement in the DOC1021 program represents an important milestone for the company and demonstrates a potential clinical application for its NTxscribe technology.
As personalized cancer therapies continue to advance, reliable manufacturing will remain an essential component of successful clinical translation.
The ability to efficiently amplify patient-derived tumor mRNA while preserving the full-length characteristics of the tumor transcriptome could provide important advantages for personalized dendritic cell vaccine development.
For the DOC1021 program, the technology is helping researchers address a particularly challenging manufacturing step while supporting the production of an individualized cancer immunotherapy being evaluated in patients with refractory melanoma.
For NTx Bio, the clinical use of NTxscribe CORE also provides an opportunity to demonstrate how continuous-flow manufacturing, automation, and closed-system processing can help overcome some of the production challenges associated with next-generation biotherapeutics.
The company intends to continue advancing its NTxscribe platform for translational and clinical applications, including through NTxscribe FLEX. As the cell and gene therapy field increasingly moves toward personalized treatments and more complex biological products, manufacturing platforms that offer reproducibility, flexibility, scalability, and reduced manual intervention could become essential to bringing innovative therapies from research laboratories to patients.
About NTx Bio
NTx Bio, based in Rio Rancho, New Mexico, is revolutionizing biomanufacturing with cutting-edge solutions tailored to the demands of modern research and personalized medicine. NTx Bio is developing innovative systems like NTxscribe® and NTxpress® to enable the sustainable production of RNA and protein therapeutics, offering scalability from personalized doses to mass-market volumes. Discover how NTx Bio is enabling the future of medicine at www.ntxbio.com.
About Diakonos Oncology Corp.
Diakonos Oncology Corp., based in Houston, Texas, is a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers. Diakonos’ lead program, DOC1021 (dubodencel), is a first-in-class, patient-derived doubly-loaded dendritic cell vaccine in clinical development for glioblastoma, pancreatic ductal adenocarcinoma, and refractory melanoma.